Regulation of myofibroblast dedifferentiation in pulmonary fibrosis.

IF 5.8 2区医学 Q1 Medicine Respiratory Research Pub Date : 2024-07-18 DOI:10.1186/s12931-024-02898-9

Xuetao Ju, Kai Wang, Congjian Wang, Chenxi Zeng, Yi Wang, Jun Yu

{"title":"Regulation of myofibroblast dedifferentiation in pulmonary fibrosis.","authors":"Xuetao Ju, Kai Wang, Congjian Wang, Chenxi Zeng, Yi Wang, Jun Yu","doi":"10.1186/s12931-024-02898-9","DOIUrl":null,"url":null,"abstract":"<p><p>Idiopathic pulmonary fibrosis is a lethal, progressive, and irreversible condition that has become a significant focus of medical research due to its increasing incidence. This rising trend presents substantial challenges for patients, healthcare providers, and researchers. Despite the escalating burden of pulmonary fibrosis, the available therapeutic options remain limited. Currently, the United States Food and Drug Administration has approved two drugs for the treatment of pulmonary fibrosis-nintedanib and pirfenidone. However, their therapeutic effectiveness is limited, and they cannot reverse the fibrosis process. Additionally, these drugs are associated with significant side effects. Myofibroblasts play a central role in the pathophysiology of pulmonary fibrosis, significantly contributing to its progression. Consequently, strategies aimed at inhibiting myofibroblast differentiation or promoting their dedifferentiation hold promise as effective treatments. This review examines the regulation of myofibroblast dedifferentiation, exploring various signaling pathways, regulatory targets, and potential pharmaceutical interventions that could provide new directions for therapeutic development.</p>","PeriodicalId":49131,"journal":{"name":"Respiratory Research","volume":null,"pages":null},"PeriodicalIF":5.8000,"publicationDate":"2024-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11264880/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Respiratory Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12931-024-02898-9","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Idiopathic pulmonary fibrosis is a lethal, progressive, and irreversible condition that has become a significant focus of medical research due to its increasing incidence. This rising trend presents substantial challenges for patients, healthcare providers, and researchers. Despite the escalating burden of pulmonary fibrosis, the available therapeutic options remain limited. Currently, the United States Food and Drug Administration has approved two drugs for the treatment of pulmonary fibrosis-nintedanib and pirfenidone. However, their therapeutic effectiveness is limited, and they cannot reverse the fibrosis process. Additionally, these drugs are associated with significant side effects. Myofibroblasts play a central role in the pathophysiology of pulmonary fibrosis, significantly contributing to its progression. Consequently, strategies aimed at inhibiting myofibroblast differentiation or promoting their dedifferentiation hold promise as effective treatments. This review examines the regulation of myofibroblast dedifferentiation, exploring various signaling pathways, regulatory targets, and potential pharmaceutical interventions that could provide new directions for therapeutic development.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

肺纤维化中对肌成纤维细胞去分化的调控。

特发性肺纤维化是一种致命、进行性和不可逆的疾病，由于其发病率不断上升，已成为医学研究的一个重要焦点。这一上升趋势给患者、医疗服务提供者和研究人员带来了巨大挑战。尽管肺纤维化的负担不断加重，但现有的治疗方案仍然有限。目前，美国食品和药物管理局已批准了两种治疗肺纤维化的药物--宁替达尼和吡非尼酮。然而，这两种药物的疗效有限，无法逆转肺纤维化的进程。此外，这些药物还伴有明显的副作用。肌成纤维细胞在肺纤维化的病理生理学中起着核心作用，对肺纤维化的进展起着重要作用。因此，旨在抑制肌成纤维细胞分化或促进其去分化的策略有望成为有效的治疗方法。这篇综述研究了肌成纤维细胞去分化的调控，探讨了各种信号通路、调控靶点和潜在的药物干预，从而为治疗开发提供了新的方向。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Respiratory Research RESPIRATORY SYSTEM-

CiteScore

9.70

自引率

1.70%

发文量

314

审稿时长

4-8 weeks

期刊介绍： Respiratory Research publishes high-quality clinical and basic research, review and commentary articles on all aspects of respiratory medicine and related diseases. As the leading fully open access journal in the field, Respiratory Research provides an essential resource for pulmonologists, allergists, immunologists and other physicians, researchers, healthcare workers and medical students with worldwide dissemination of articles resulting in high visibility and generating international discussion. Topics of specific interest include asthma, chronic obstructive pulmonary disease, cystic fibrosis, genetics, infectious diseases, interstitial lung diseases, lung development, lung tumors, occupational and environmental factors, pulmonary circulation, pulmonary pharmacology and therapeutics, respiratory immunology, respiratory physiology, and sleep-related respiratory problems.